Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST)

Schizophrenia Research

Volumn 115, Issue 2-3, 2009, Pages 97-103

  Boter, Han ^a   Peuskens, Joseph ^b   Libiger, Jan ^c   Fleischhacker, W Wolfgang ^d   Davidson, Michael ^e   Galderisi, Silvana ^f   Kahn, René S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e SHEBA MEDICAL CENTER   (Israel)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

First episode patients; Multicenter study; Randomized clinical trial; Remission; Schizophrenia; Treatment response

Indexed keywords

AMISULPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CROSS-CULTURAL COMPARISON; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; ISRAEL; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECURRENCE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 71649098113     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.09.019     Document Type: Article

References (18)

1. Andreasen N.C., Carpenter W., Kane J.M., Lasser R.A., Marder S.R., and Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162 (2005) 441-449
2. Emsley R., Oosthuizen P.P., Kidd M., Koen L., Niehaus D.J., and Turner H.J. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J. Clin. Psychiatry 67 (2006) 1707-1712
3. Emsley R., Rabinowitz J., and Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry 163 (2006) 743-745
4. Emsley R., Rabinowitz J., and Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr. Res. 89 (2007) 129-139
5. Emsley R.A., and Risperidone Working Group. Risperidone in the treatment of first episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr. Bull. 25 (1999) 721-729
6. Fleischhacker W.W., Keet I.P., and Kahn R.S. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr. Res. 78 (2005) 147-156
7. Galderisi S., Davidson M., Kahn R.S., Mucci A., Boter H., Gheorghe M.D., Rybakowski J.K., Libiger J., Dollfus S., López-Ibor J.J., Peuskens J., Hranov L.G., and Fleischhacker W.W. Correlates of cognitive impairment in first episode schizophrenia: the EUFEST Study. Schizophr. Res. XX (2009) XXX-XXX. SCHRES-D-09-00139
8. Gerlach J., Korsgaard S., Clemmesen P., Lauersen A.M., Magelund G., Noring U., Povlsen U.J., Bech P., and Casey D.E. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr. Scand. 87 (1993) 244-252
9. Guy W. Clinical Global Impressions (CGI) scale. In: Rush Jr. A.J., Pincus H.A., First M.B., Blacker D., Endicott J., Keith S.J., Phillips K.A., Ryan N.D., Smith Jr. G.R., Tsuang M.T., Widiger T.A., and Zarin D.A. (Eds). Handbook of Psychiatric Measures (2000), American Psychiatric Association, Washington, DC 100-102
10. Jones S.H., Thornicroft G., Coffey M., and Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry 166 (1995) 654-659
11. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., and Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 (2008) 1085-1097
12. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
13. Kemp R., Hayward P., Applewhaite G., Everitt B., and David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 312 (1996) 345-349
14. Leucht S., Davis J.M., Engel R.R., Kane J.M., and Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 32 (2007) 1903-1910
15. Leucht S., Heres S., Hamann J., and Kane J.M. Methodological issues in current antipsychotic drug trials. Schizophr. Bull. 34 (2008) 275-285
16. Pocock S.J. Clinical Trials: A Practical Approach (1993), Wiley, Chichester
17. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., and Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 suppl 20 (1998) 22-33
18. van Os J., Burns T., Cavallaro R., Leucht S., Peuskens J., Helldin L., Bernardo M., Arango C., Fleischhacker W., Lachaux B., and Kane J.M. Standardized remission criteria in schizophrenia. Acta Psychiatr. Scand. 113 (2006) 91-95